Certara, Inc..
CERT.US | Research and experimental development on natural sciences and engineering
Certara, Inc. is a global biosimulation company that accelerates medicines to patients using model-informed drug development. They provide software and services to biopharmaceutical companies and regulatory agencies to optimize drug development and improve patient outcomes. Their offerings include b...Show More
Better Health for All
20
Certara's business model inherently supports the development of new medicines, indirectly contributing to improved health outcomes. Certara's software and services facilitate the development and approval of new medicines
1
,
2
,
3
,
4
,
5
. Certara's customers received 90% of US FDA novel drug approvals in 2022
6
,
7
,
8
. Certara's technology was used to support the development of a drug for moderate/severe COVID-19
9
. Certara's software boasts a 96% approval rate across over 300 submissions
10
,
11
. Certara's R&D investment is significant
12
. The company's advanced pharmaceutical modeling and simulation software platform has a market growth rate of 12.4%
13
. The company's regulatory submission success rate is 92%
14
. The company's AI solution adoption rate among top-tier pharmaceutical firms is 68%
15
.
Fair Money & Economic Opportunity
0
Certara, Inc. is a biosimulation company, not a financial institution. It does not offer lending or deposit services to consumers, nor does it manage customer finance data or provide debt products.
1
Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcome, profit reinvestment, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its core business model.
2
While one article mentions John Reynders, founder and CEO of Latent Strategies, LLC, an EdTech start-up focused on financial literacy,
3
this is a personal endeavor of an individual and not an initiative of Certara, Inc. itself.
Fair Pay & Worker Respect
0
No evidence available to assess Certara, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
The provided articles do not contain specific, concrete data points for any of the KPIs related to Fair Trade & Ethical Sourcing.
1
Information on fair-trade certifications, supplier audit frequencies, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, high-risk material spend, or supplier diversity spend is not available in the evidence.
2
Honest & Fair Business
-40
Certara has a formal whistleblower policy, which includes a dedicated email address and a 24/7 compliance line.
1
The company emphasizes the confidentiality and independence of its reporting mechanism.
2
However, there is no specific evidence provided regarding independent investigation processes, training frequency, uptake rates, or resolution metrics.
3
No information is available for regulatory fines, transparency index scores, financial restatements, audit coverage, ESG controversy index, complaint resolution time, board conflict-free percentage, anti-corruption policy details, or third-party verification of ethical claims.
4
Kind to Animals
10
Certara is a service-oriented company with no animal-derived products or direct animal testing operations, hence several KPIs are not applicable. The company's core business involves biosimulation and AI-enabled models, which serve as alternatives to traditional animal testing in drug development.
1
Certara launched its Non-Animal Navigator™ solution in 2025
2
to help biopharmaceutical companies transition to non-animal methods (NAMs) for preclinical safety studies, aligning with the FDA's Roadmap to Reducing Animal Testing.
3
Certara's Simcyp PBPK Simulator is used for 80% of drugs leveraging PBPK for FDA approval,
4
indicating that non-animal assays are standard in regulatory submissions. The company invested 9% of its revenue in R&D in 2024,
5
with a focus on developing additional functionality for biosimulation.
6
Certara participates in the EU-ToxRisk project, an international effort with 39 partner organizations and a 30 Million € investment, to develop animal-free toxicology tests.
7
Certara actively engages with regulatory agencies like the FDA and EMA,
8
and its solutions are designed to help clients comply with the FDA Modernization Act 2.0
9
and the FDA Roadmap, which aim to phase out animal testing.
10
No War, No Weapons
0
Certara's core business is biosimulation technology and solutions for Model-Informed Drug Development in the global biopharmaceutical industry, focused on accelerating medicines to patients.
1
There is no evidence suggesting the development or sale of dual-use products with military applications.
2
Planet-Friendly Business
-50
Certara's total Scope 1, 2, and 3 greenhouse gas emissions for 2024 were 7,073 tCO₂e, representing a 21.51% reduction from 2023.
1
The company has committed to developing science-based targets (SBTi) for GHG emission reduction, with validation pending.
2
Certara's climate goals typically focus on 2050 net-zero commitments.
3
The company reports on climate-related risks and opportunities in its periodic ESG Report.
4
Respect for Cultures & Communities
0
The provided articles do not contain specific, quantitative data points or concrete facts relevant to any of the Key Performance Indicators for 'Respect for Cultures & Communities'. The information available focuses on general company culture, overall ESG performance (including R&D investment, GHG emissions, and regulatory licenses), and employee-related recognitions, none of which directly address community engagement, cultural preservation, local employment ratios, or grievance mechanisms as defined by the rubric.
1
Safe & Smart Tech
10
Certara reported no known cybersecurity incidents with material impact in its 2024-02-29 10-K filing, and no incidents of unauthorized data use.
1
The company conducts annual cybersecurity awareness training for employees.
2
Certara utilizes vulnerability scanning, penetration testing, and threat intelligence.
3
The company's Trust Center and 10-K filing indicate compliance with a comprehensive set of standards and regulations, including ISO/IEC 27001:2022, NIST CSF, NIST 800-53 Rev. 5, GDPR, EU-US DPF, Swiss-US DPF, UK Extension to EU-US DPF, SOX, CIS Top 20, OWASP Top 10, and Security by Design.
4
Zero Waste & Sustainable Products
-40
Certara has implemented four waste reduction initiatives, including minimizing consumption, promoting two-sided printing and copying, supporting recycling, and ensuring responsible disposal of materials.
1
The company has established company-wide waste reduction targets with timelines, and it has committed to developing science-based targets for GHG emission reduction through the SBTi.
2
Certara also has waste-related requirements for all tier-1 suppliers, expecting them to uphold high standards of environmental stewardship and potentially giving preference to those demonstrating progress on material sustainability topics.
3